Impact of Positive End-expiratory Pressure on Hepatic Venous Flow

NCT ID: NCT02700581

Last Updated: 2016-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the difference in the impact of moderate positive end-expiratory pressure (PEEP) on hepatic venous flow Doppler in patients undergoing cardiac surgery: conventional versus protective ventilation strategy The possible changes in forward and backward flows (Doppler profiles) of hepatic venous flow at different degrees of PEEP in conventional and protective ventilation strategies are analyzed by using intraoperative transesophageal echocardiography (TEE) in patients undergoing cardiac surgery .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Following data would be determined after 5 min-exposure volume controlled ventilation employing tidal volume of 10 ml/kg and 6 ml/kg with low PEEP (with 2 mmHg) and moderate PEEP (7 mmHg) during remifentanil-based anesthesia (1.0 mcg/kg/min) for cardiac surgery (n=12)

1. sum of forward hepatic venous flow
2. sum of backward hepatic venous flow
3. peak velocity of diastolic hepatic venous flow
4. lung compliance
5. peak airway pressure
6. mean airway pressure
7. other pressure derived hemodynamic parameters:heart rate; systolic, diastolic, and mean blood pressures; systolic, diastolic, and mean pulmonary artery pressures; central venous pressure (CVP), pulmonary capillary

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Valvular Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

low PEEP conventional ventilation

PEEP 2 mmHg tidal volume 10ml/kg

Group Type ACTIVE_COMPARATOR

low PEEP conventional ventilation

Intervention Type PROCEDURE

moderate PEEP conventional ventilation

PEEP 7 mmHg tidal volume 10ml/kg

Group Type EXPERIMENTAL

moderate PEEP conventional ventilation

Intervention Type PROCEDURE

low PEEP protective ventilation

PEEP 2 mmHg with tidal volume 6 ml/kg

Group Type EXPERIMENTAL

low PEEP protective ventilation

Intervention Type PROCEDURE

moderate PEEP protective ventilation

PEEP 7 mmHg tidal volume 6ml/kg

Group Type EXPERIMENTAL

moderate PEEP protective ventilation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

low PEEP conventional ventilation

Intervention Type PROCEDURE

moderate PEEP conventional ventilation

Intervention Type PROCEDURE

low PEEP protective ventilation

Intervention Type PROCEDURE

moderate PEEP protective ventilation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing cardiac surgery
* Patients provide written informed consents

Exclusion Criteria

* Re-do or tri-do surgery
* Patients with active infection
* Patients with endocrine disease
* Patients ischemic heart disease
* patients with tricuspid valve regurgitation greater than mild degree
Minimum Eligible Age

19 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Konkuk University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tae-Yop Kim, MD PhD

Professor of Anesthesiology

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Tae-Yop Kim, MD, PhD

Role: CONTACT

+82222926942

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KUH000000 TBD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.